In OSCC, targeting necroptosis with inhibitors, such as NEC-1, or inducers, such as acetylshikonin, shows potential for modulating tumor progression and the tumor immune microenvironment, presenting promising avenues for therapeutic intervention. The gene discussed is PCSK1; the disease is neoplasm.